VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | The role of PHF19 in multiple myeloma & its potential as a therapeutic target

Tengteng Yu, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the impact of PHF19 overexpression in multiple myeloma, commenting on the results of a recent study that reported that PHF19 overexpression induces resistance to anti-CD38 monoclonal antibodies and increases regulatory T-cell levels in patients treated with CAR-T therapy, and highlighting the potential of PHF19 as a therapeutic target in multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter